Stock Price & Analysis

Based on the provided data and current market conditions, FMS stock appears to be in a challenging position. Here's the analysis:

Technical Analysis

• Current price at $24.17, showing weakness with a -0.74% decline in regular trading hours
• Post-market showing some recovery with +1.74% gain
• RSI at 55.92 indicates neutral momentum, neither overbought nor oversold

Analyst Sentiment Recent analyst actions show mixed views:

• Truist Securities maintained Hold rating with price target raised to $25 (January 2025)
• The consensus among analysts suggests a Hold rating
• Price targets range from $23-$25, indicating limited upside potential

Market Position

• FMS is the largest dialysis provider globally
• Services account for ~80% of revenue with higher margin products contributing 20%
• Company faces challenges in inventory management and cost pressures

Key Considerations

• Recent analyst reports highlight concerns about:
  • Cost-focused government backdrop
  • Healthcare services sector facing mixed outlook
  • Cash flow generation remains solid despite challenges

Recommendation SELL recommendation at current levels based on:

1. Limited upside potential according to analyst targets
2. Challenging healthcare services environment
3. Technical indicators showing weakness
4. Better opportunities may exist in other healthcare stocks

Based on recent analyst ratings and technical indicators, FMS stock is projected to reach $27-28 by end of 2025, driven by the company's strong market position in dialysis services and positive analyst upgrades from Berenberg Bank with a higher price target of €55. Technical analysis shows the stock trading above its 20-day and 60-day SMAs of $23.97 and $23.15 respectively, indicating bullish momentum, while Fibonacci resistance levels suggest room for upward movement to $25.82.

The stock price forecast considers FMS's dominant 35% market share in global dialysis products and its integrated business model where services contribute 80% of revenue, positioning it well for steady growth despite some analysts maintaining cautious stances.

The S1 support level for FMS Stock is $24.23 ,The R1 resistant level for FMS Stock is $25.06.

As of the end of day on 2025-02-12, the price of FMS Stock was $24.05.

The target price for FMS Stock according to analyst rating is 26.63, with the highest price target at 28.90 and the lowest at 25.00. Analysts have a Hold rating on FMS Stock overall.

The market cap of FMS is $14.2B.

Based on the financial data and recent analyst reports, here's a concise analysis of FMS's valuation:

FMS shows improving profitability with net margin expanding from 2.5% to 5.5% over the past three quarters, indicating operational efficiency gains. The P/E ratio of 19.5x in Q2 2024 is reasonable for the healthcare sector, while the EV/EBITDA of 6.5x suggests the company is not overvalued compared to industry peers.

The company's current P/B ratio of 0.82 indicates it's trading below book value, suggesting potential undervaluation. The dividend yield of 3.02% provides decent income support.

Recent analyst actions show mixed views - Warburg Research upgraded to Hold with €43 target, while JP Morgan maintains Sell with €37.30 target. However, Berenberg Bank remains bullish with a Buy rating and €55 target, indicating significant upside potential.

The technical indicators show RSI at 55.92, suggesting neutral momentum rather than overbought conditions. The stock is trading above both 20-day (23.97) and 60-day (23.15) moving averages, indicating positive medium-term trend.

Based on improving fundamentals, reasonable valuation metrics, and positive technical setup, FMS appears fairly valued to slightly undervalued at current levels.

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Based on the provided data and market analysis, here's the price prediction for FMS stock by 2030:

FMS stock is projected to reach $35-38 by 2030, driven by its dominant position as the world's largest dialysis provider with 35% market share and strong product margins. Recent analyst upgrades from Warburg Research and Berenberg Bank with higher price targets indicate growing confidence in the company's business model. The company's integrated dialysis business structure and high-margin product segment accounting for 20% of revenue provides sustainable competitive advantages for long-term growth.

The technical analysis shows FMS is currently trading at $24.17 with an RSI of 55.92, indicating a neutral momentum that supports steady price appreciation over the long term.

FMS has a total of 112382 employees.